The Transcription Factor Twist1 Has a Significant Role in Mycosis Fungoides (MF) Cell Biology: An RNA Sequencing Study of 40 MF Cases

The purpose of this RNA sequencing study was to investigate the biological mechanism underlying how the transcription factors (TFs) Twist1 and Zeb1 influence the prognosis of mycosis fungoides (MF). We used laser-captured microdissection to dissect malignant T-cells obtained from 40 skin biopsies from 40 MF patients with stage I–IV disease. Immunohistochemistry (IHC) was used to determinate the protein expression levels of Twist1 and Zeb1. Based on RNA sequencing, principal component analysis (PCA), differential expression (DE) analysis, ingenuity pathway analysis (IPA), and hub gene analysis were performed between the high and low Twist1 IHC expression cases. The DNA from 28 samples was used to analyze the TWIST1 promoter methylation level. In the PCA, Twist1 IHC expression seemed to classify cases into different groups. The DE analysis yielded 321 significant genes. In the IPA, 228 significant upstream regulators and 177 significant master regulators/causal networks were identified. In the hub gene analysis, 28 hub genes were found. The methylation level of TWIST1 promoter regions did not correlate with Twist1 protein expression. Zeb1 protein expression did not show any major correlation with global RNA expression in the PCA. Many of the observed genes and pathways associated with high Twist1 expression are known to be involved in immunoregulation, lymphocyte differentiation, and aggressive tumor biology. In conclusion, Twist1 might be an important regulator in the disease progression of MF.

[1]  Jimin Cao,et al.  Values of OAS gene family in the expression signature, immune cell infiltration and prognosis of human bladder cancer , 2022, BMC Cancer.

[2]  Zude Chen,et al.  Fc Fragment of IgE Receptor Ig (FCER1G) acts as a key gene involved in cancer immune infiltration and tumour microenvironment , 2022, Immunology.

[3]  Linqing Wu,et al.  GJA1 reverses arsenic-induced EMT via modulating MAPK/ERK signaling pathway. , 2022, Toxicology and Applied Pharmacology.

[4]  P. Porcu,et al.  Dermal fibroblasts promote cancer cell proliferation and exhibit fibronectin overexpression in early mycosis fungoides. , 2022, Journal of dermatological science.

[5]  K. Tsai,et al.  Genomic and single-cell landscape reveals novel drivers and therapeutic vulnerabilities of transformed cutaneous T-cell lymphoma. , 2022, Cancer discovery.

[6]  W. Kempf,et al.  Cutaneous T‐cell lymphomas—An update 2021 , 2021, Hematological oncology.

[7]  M. Velásquez-Lopera,et al.  Cell signaling in cutaneous T‐cell lymphoma microenvironment: promising targets for molecular‐specific treatment , 2021, International journal of dermatology.

[8]  T. Tan,et al.  Cytoskeletal Dynamics in Epithelial-Mesenchymal Transition: Insights into Therapeutic Targets for Cancer Metastasis , 2021, Cancers.

[9]  U. Wehkamp,et al.  Role of B-cells in Mycosis Fungoides , 2021, Acta dermato-venereologica.

[10]  Jun Yao,et al.  Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy , 2021, Nature Communications.

[11]  Fan Yang,et al.  Long noncoding RNA SATB1-AS1 contributes to the chemotherapy resistance through the microRNA-580/ 2’-5’-oligoadenylate synthetase 2 axis in acute myeloid leukemia , 2021, Bioengineered.

[12]  L. Michel,et al.  The value of five blood markers in differentiating mycosis fungoides and Sézary syndrome: a validation cohort * , 2020, The British journal of dermatology.

[13]  T. Krejsgaard,et al.  Cellular Interactions and Inflammation in the Pathogenesis of Cutaneous T-Cell Lymphoma , 2020, Frontiers in Cell and Developmental Biology.

[14]  Jing Liu,et al.  Identification of Key Genes and Pathways in Myeloma side population cells by Bioinformatics Analysis , 2020, International journal of medical sciences.

[15]  Yujie Zhang,et al.  Prognostic characterization of OAS1/OAS2/OAS3/OASL in breast cancer , 2020, BMC Cancer.

[16]  Tzong-Yi Lee,et al.  Computational analysis for identification of the extracellular matrix molecules involved in endometrial cancer progression , 2020, PloS one.

[17]  J. O’Sullivan,et al.  Characterising the prognostic potential of HLA-DR during colorectal cancer development , 2020, Cancer Immunology, Immunotherapy.

[18]  Ying Xu,et al.  ERK/MAPK signalling pathway and tumorigenesis , 2020, Experimental and therapeutic medicine.

[19]  Tiansheng Zeng,et al.  Enhanced expression of FCER1G predicts positive prognosis in multiple myeloma , 2020, Journal of Cancer.

[20]  Y. Soini,et al.  Twist and Zeb1 expression identify mycosis fungoides patients with low risk of disease progression , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[21]  M. Zhou,et al.  Deciphering Immune-Associated Genes to Predict Survival in Clear Cell Renal Cell Cancer , 2019, BioMed research international.

[22]  M. Sugaya,et al.  Possible therapeutic applicability of galectin-9 in cutaneous T-cell lymphoma. , 2019, Journal of dermatological science.

[23]  E. Jaffe,et al.  The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. , 2019, Blood.

[24]  Damian Szklarczyk,et al.  STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets , 2018, Nucleic Acids Res..

[25]  Jan Gorodkin,et al.  Cytoscape stringApp: Network analysis and visualization of proteomics data , 2018, bioRxiv.

[26]  Qing‐Yu He,et al.  Significance of integrin-linked kinase (ILK) in tumorigenesis and its potential implication as a biomarker and therapeutic target for human cancer. , 2019, American journal of cancer research.

[27]  Seon-Young Kim,et al.  Opposite functions of GSN and OAS2 on colorectal cancer metastasis, mediating perineural and lymphovascular invasion, respectively , 2018, PloS one.

[28]  G. Ren,et al.  LITAF is a potential tumor suppressor in pancreatic cancer , 2017, Oncotarget.

[29]  Xinghuan Wang,et al.  Co-expression network analysis identified FCER1G in association with progression and prognosis in human clear cell renal cell carcinoma , 2017, International journal of biological sciences.

[30]  F. Kruyt,et al.  EMT‐ and MET‐related processes in nonepithelial tumors: importance for disease progression, prognosis, and therapeutic opportunities , 2017, Molecular oncology.

[31]  Mingyao Liu,et al.  Targeting Twist expression with small molecules. , 2017, MedChemComm.

[32]  Z. Chen,et al.  Multiple biological functions of Twist1 in various cancers , 2017, Oncotarget.

[33]  Y. Zhang,et al.  Integrin-linked kinase overexpression promotes epithelial-mesenchymal transition via nuclear factor-κB signaling in colorectal cancer cells. , 2016, World journal of gastroenterology.

[34]  S. Perner,et al.  NDUFA4 expression in clear cell renal cell carcinoma is predictive for cancer-specific survival. , 2015, American journal of cancer research.

[35]  N. Lu,et al.  A new role for the PI3K/Akt signaling pathway in the epithelial-mesenchymal transition , 2015, Cell adhesion & migration.

[36]  J. Becker,et al.  Ectopic expression of a novel CD22 splice-variant regulates survival and proliferation in malignant T cells from cutaneous T cell lymphoma (CTCL) patients , 2015, Oncotarget.

[37]  M. Tschan,et al.  TWIST1 and TWIST2 promoter methylation and protein expression in tumor stroma influence the epithelial-mesenchymal transition-like tumor budding phenotype in colorectal cancer , 2014, Oncotarget.

[38]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[39]  A. Puisieux,et al.  The emerging role of Twist proteins in hematopoietic cells and hematological malignancies , 2014, Blood Cancer Journal.

[40]  Andreas Krämer,et al.  Causal analysis approaches in Ingenuity Pathway Analysis , 2013, Bioinform..

[41]  J. Merlio,et al.  CD20 Antigen May Be Expressed by Reactive or Lymphomatous Cells of Transformed Mycosis Fungoides: Diagnostic and Prognostic Impact , 2013, The American journal of surgical pathology.

[42]  E. Jantunen,et al.  Biological roles and prognostic values of the epithelial–mesenchymal transition‐mediating transcription factors Twist, ZEB1 and Slug in diffuse large B‐cell lymphoma , 2013, Histopathology.

[43]  Zhiwei Wang,et al.  Degradation of the transcription factor Twist, an oncoprotein that promotes cancer metastasis. , 2013, Discovery medicine.

[44]  A. Aplin,et al.  TWIST1 is an ERK1/2 effector that promotes invasion and regulates MMP-1 expression in human melanoma cells. , 2012, Cancer research.

[45]  M. Goswami,et al.  Increased Twist expression in advanced stage of mycosis fungoides and Sézary syndrome , 2012, Journal of cutaneous pathology.

[46]  M. Smyth,et al.  CD73: a potent suppressor of antitumor immune responses. , 2012, Trends in immunology.

[47]  Q. Rao,et al.  PIG7, transactivated by AML1, promotes apoptosis and differentiation of leukemia cells with AML1–ETO fusion gene , 2012, Leukemia.

[48]  Jun Qin,et al.  Phosphorylation of serine 68 of Twist1 by MAPKs stabilizes Twist1 protein and promotes breast cancer cell invasiveness. , 2011, Cancer research.

[49]  J. Xie,et al.  LITAF and TNFSF15, two downstream targets of AMPK, exert inhibitory effects on tumor growth , 2011, Oncogene.

[50]  Richard Beyer,et al.  TWIST1 promotes invasion through mesenchymal change in human glioblastoma , 2010, Molecular Cancer.

[51]  J. Whitsett,et al.  Signaling pathways in the epithelial origins of pulmonary fibrosis , 2010, Cell cycle.

[52]  Leonard J Foster,et al.  Pseudopodial actin dynamics control epithelial-mesenchymal transition in metastatic cancer cells. , 2010, Cancer research.

[53]  Luigi Naldini,et al.  FcRgamma activation regulates inflammation-associated squamous carcinogenesis. , 2010, Cancer cell.

[54]  H. Salih,et al.  Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. , 2009, Cancer research.

[55]  Raghu Kalluri,et al.  The basics of epithelial-mesenchymal transition. , 2009, The Journal of clinical investigation.

[56]  R. Weinberg,et al.  Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits , 2009, Nature Reviews Cancer.

[57]  G. Berx,et al.  The role of the ZEB family of transcription factors in development and disease , 2009, Cellular and Molecular Life Sciences.

[58]  Robert A. Weinberg,et al.  Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. , 2008, Developmental cell.

[59]  C. Heldin,et al.  Signaling networks guiding epithelial–mesenchymal transitions during embryogenesis and cancer progression , 2007, Cancer science.

[60]  S. Tuomela,et al.  Th1 Response and Cytotoxicity Genes Are Down-Regulated in Cutaneous T-Cell Lymphoma , 2006, Clinical Cancer Research.

[61]  R. Willemze,et al.  Aberrant Expression of the Tyrosine Kinase Receptor EphA4 and the Transcription Factor Twist in Sézary Syndrome Identified by Gene Expression Analysis , 2004, Cancer Research.

[62]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[63]  R. Willemze,et al.  DISTINCTIVE ADHESION PATHWAYS ARE INVOLVED IN EPITHELIOTROPIC PROCESSES AT DIFFERENT SITES , 1996, The Journal of pathology.

[64]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[65]  M. Matejka,et al.  Epidermal Langerhans cells in mycosis fungoides and Sézary syndrome. , 1983, Wiener Klinische Wochenschrift.